niclosamide has been researched along with Obesity in 3 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide piperazine salt may hold the promise to become an alternative to NEN as a drug lead for the treatment of obesity and T2D." | 7.91 | Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. ( Alasadi, A; Guo, J; Huang, Q; Jin, S; Tao, H, 2019) |
| "To assess the anti-obesity effects of niclosamide on mice with induced obesity." | 7.85 | Niclosamide as an anti-obesity drug: an experimental study. ( Al-Gareeb, AI; Aljubory, KD; Alkuraishy, HM, 2017) |
| "Niclosamide piperazine salt may hold the promise to become an alternative to NEN as a drug lead for the treatment of obesity and T2D." | 3.91 | Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. ( Alasadi, A; Guo, J; Huang, Q; Jin, S; Tao, H, 2019) |
| "To assess the anti-obesity effects of niclosamide on mice with induced obesity." | 3.85 | Niclosamide as an anti-obesity drug: an experimental study. ( Al-Gareeb, AI; Aljubory, KD; Alkuraishy, HM, 2017) |
| "Metabolic disorders such as type 2 diabetes, fatty liver disease, hyperlipidemia, and obesity commonly co-occur but clinical treatment options do not effectively target all disorders." | 2.44 | Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice. ( Alexopoulos, SJ; Beretta, M; Byrne, FL; Cantley, J; Chen, SY; Garcia, CJ; Hoehn, KL; Larance, M; Olzomer, EM; Philp, A; Salamoun, JM; Santos, WL; Shah, DP; Smith, GC; Turner, N, 2024) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SY | 1 |
| Beretta, M | 1 |
| Olzomer, EM | 1 |
| Alexopoulos, SJ | 1 |
| Shah, DP | 1 |
| Byrne, FL | 1 |
| Salamoun, JM | 1 |
| Garcia, CJ | 1 |
| Smith, GC | 1 |
| Larance, M | 1 |
| Philp, A | 1 |
| Turner, N | 1 |
| Santos, WL | 1 |
| Cantley, J | 1 |
| Hoehn, KL | 1 |
| Guo, J | 1 |
| Tao, H | 1 |
| Alasadi, A | 1 |
| Huang, Q | 1 |
| Jin, S | 1 |
| Al-Gareeb, AI | 1 |
| Aljubory, KD | 1 |
| Alkuraishy, HM | 1 |
3 other studies available for niclosamide and Obesity
| Article | Year |
|---|---|
Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
Topics: Animals; Caloric Restriction; Diabetes Mellitus, Type 2; Ethanolamine; Ethanolamines; Female; Mice; | 2024 |
Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Mice | 2019 |
Niclosamide as an anti-obesity drug: an experimental study.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Cholesterol; Diet, High-Fat; Eating; Insul | 2017 |